Coagulation factor concentrates fail to restore alterations in fibrin formation caused by rivaroxaban or dabigatran in studies with flowing blood from treated healthy volunteers

We evaluated the hemostatic alterations in blood from healthy individuals treated for 5 days with direct oral anticoagulants (DOACs) rivaroxaban (20 mg/day) or dabigatran (150 mg/12 h) in a single blind clinical trial with crossover assignment (NCT01478282). We assessed the potential of prothrombin complex concentrates (PCCs), activated PCCs or rFVIIa, when added ex vivo, to reverse the alterations caused by these DOACs. Blood was drawn at Cmax after the last dose of each DOAC and modifications in coagulation biomarkers evaluated using a series of tests performed under steady conditions including: routine coagulation, thrombin generation and thromboelastometry assays.

Source: Transfusion Medicine Reviews - August 8, 2015 Category: Hematology Authors: Eduardo Arellano-Rodrigo, Irene Lopez-Vilchez, Ana M. Galan, Patricia Molina, Joan Carles Reverter, Xavier Carné, Jaume Villalta, Dolors Tassies, Miguel Lozano, Maribel Díaz-Ricart, Gines Escolar Source Type: research